Overview

A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
A study to verify the superiority of ramosetron hydrochloride (Irribow Tablets) to placebo for male patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
Phase:
Phase 4
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Ramosetron